These developments, plus the recent description of an isoform-specific small molecule Pak inhibitor that can discriminate between Pak1 and Pak2, suggest that such agents may find clinical utility in treating various human malignancies that require Pak function, including CRC. This evidence concerns the gene PAK2 and colorectal carcinoma.